## **COMBINED DECLARATION AND POWER OF ATTORNEY**

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed and for which a patent is sought on the invention entitled:

## METHODS FOR IDENTIFYING COMPOUNDS CAPABLE OF MODULATING THE HYDROLASE ACTIVITY OF CLCA PROTEIN

he spe	cification of which:					
o n	is attached hereto.					
OR on	was filed on	with Express Mail No.	(Application Number not yet known).			
OR	was filed on <u>3 March 2005</u> as United States Application Number or PCT International Application Number <u>PCT/SE2005/000316</u> and was amended on (if applicable).					
ncludi		riewed and understand the contents of any amendment referred to above.	the above-identified specification,			
§1.56.	I acknowledge the duty to d	isclose information which is material	to patentability as defined in 37 CFR			
I hereby claim the benefit under Title 35, United States Code, §119(e)(1) of any United States provisional application(s) listed below:						
·` ·	U.S. Serial No.	Filing Date	Status			
matter Internation of Federate	) of any PCT International app of each of the claims of this ap tional application in the mann yledge the duty to disclose all	plication designating the United States pplication is not disclosed in the prior er provided by the first paragraph of I information I know to be material to p ch became available between the filin	20 of any United States application(s), or is, listed below and, insofar as the subject United States application or PCT Fitle 35, United States Code, §112, I patentability as defined in Title 37, Code g date of the prior application and the			
	U.S. Serial No.	Filing Date	Status			



I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application designating at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

Country	Application No.	Filing Date	Priority Claimed
Sweden	0400564-1	5 March 2004	
			Yes No

I hereby appoint all registered practitioners associated with **Customer Number 26164** to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to:

## Customer Number 26164

Direct all telephone calls to JANIS K. FRASER, Ph.D., J.D., Reg. No. 34,819, at telephone number (617) 542-5070.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor:

Matti LEPISTÖ

Inventor's Signature:
Residence Address:

Lund, Sweden

Citizenship:

SE

Post Office Address:

AstraZeneca R&D Lund, SE-221 87 Lund, Sweden

Full Name of Inventor:

Krzysztof PAWLOWSKI

Inventor's Signature:

R. 1967

Date: 2006-06-20

Date: 2006-06-19

Residence Address:

Lund, Sweden

Citizenship:

PL

Post Office Address:

AstraZeneca R&D Lund, SE-221 87 Lund, Sweden